NCT04467021

Cancer and Blood Pressure Management, CARISMA Study

Active, enrolled NA Last updated 3 April 2026

What this trial tests

NA trial testing Best Practice in Cardiovascular Disorder in 61 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 October 2020

Primary endpoint
31 August 2026

31 August 2026

Quick facts

Lead sponsor	ECOG-ACRIN Cancer Research Group
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	61
Start date	29 October 2020
Primary completion	31 August 2026
Estimated completion	31 August 2026
Sites	25 locations across United States

Drugs / interventions tested

• Best Practice
• Blood Pressure Measurement
• Clinical Management
• Quality-of-Life Assessment
• Questionnaire Administration

Conditions studied

• Cardiovascular Disorder — all drugs for Cardiovascular Disorder →
• Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
• Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →
• Metastatic Thyroid Gland Medullary Carcinoma — all drugs for Metastatic Thyroid Gland Medullary Carcinoma →

Sponsor

ECOG-ACRIN Cancer Research Group

Who can join

18 and older, any sex, with Cardiovascular Disorder or Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
   Camarda N, Travers R, Yang VK, London C, et al · · 2022 · cited 49× · PMID 35179707 · DOI 10.1007/s11912-022-01224-0
2. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
   Butel-Simoes LE, Haw TJ, Williams T, Sritharan S, et al · · 2023 · cited 13× · PMID 36756872 · DOI 10.1161/hypertensionaha.122.17947
3. Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
   Ky B, Liu T, Margulies KB, Mitchell JD, et al · · 2026 · PMID 42158981 · DOI 10.1161/hypertensionaha.125.26016
4. Onco-hypertension: hypertension induced by VEGF pathway inhibition.
   Palaskas NL, Kim JH, Moreno SFL, Casso-Chapa B, et al · · 2026 · PMID 42131090 · DOI 10.3389/fcvm.2026.1748445
5. Cardiovascular Risk Assessment in Patients With Kidney Cancer: Time for New Survivorship Goals.
   Mittal K, Upshaw JN. · · 2025 · PMID 40841113 · DOI 10.1016/j.jaccao.2025.07.004